Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancer

被引：0

作者：

Blagden, S. ^{[1
]}

Olmos, D. ^{[2
]}

Sharma, R. ^{[1
]}

Barruiso, J. ^{[2
]}

Medani, H. ^{[1
]}

Versola, M. ^{[3
]}

Murray, S. ^{[3
]}

Smith, D. A. ^{[3
]}

Dar, M. M. ^{[3
]}

deBono, J. S. ^{[2
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Dept Oncol, London, England

[2] Royal Marsden Hosp, Drug Dev Unit, Sutton, Surrey, England

[3] GlaxoSmithKline Inc, Res & Dev, Res Triangle Pk, NC USA

来源：

EJC SUPPLEMENTS | 2008年 / 6卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：135 / 135

页数：1

共 45 条

[21] Phase I trial of volasertib (BI 6727), a polo-like kinase 1 (Plk1) inhibitor, in combination with cisplatin or carboplatin in patients with advanced solid tumors.
Deleporte, A.
Dumez, H.
Awada, A.
Costermans, J.
Meeus, M.
Berghmans, T.
Kaci, M. Ould
Juhel, N.
Berge, A.
Taube, T.
Schoeffski, P.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[22] A phase I dose-escalation study of the polo-like kinase 1 inhibitor volasertib (BI 6727) with two different dosing schedules in patients with advanced solid malignancies.
Lin, C.
Su, W.
Yen, C.
Cheng, A.
Lu, Y.
Hsu, C.
Su, W.
Huang, D. C.
Fritsch, H.
Voss, F.
Schreck, R.
Taube, T.
Yang, C.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[23] Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine
Bug, Gesine
Schlenk, Richard F.
Mueller-Tidow, Carsten
Luebbert, Michael
Kraemer, Alwin
Fleischer, Frank
Taube, Tillmann
Ottmann, Oliver G.
Doehner, Hartraut
BLOOD, 2010, 116 (21) : 1359 - 1359
[24] Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts
Lohse, I.
Mason, J. M.
Cao, P. J.
Pintilie, Melania
Bray, M. R.
Hedley, D. W.
ONCOTARGET, 2017, 8 (02) : 3064 - 3071
[25] Identification of naphthalimide-derivatives as novel PBD-targeted polo-like kinase 1 inhibitors with efficacy in drug-resistant lung cancer cells
Li, Pingping
Li, Yongkun
Ma, Xuesong
Li, Liangping
Zeng, Shulan
Peng, Yan
Liang, Hong
Zhang, Guohai
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 271
[26] The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma
Stewart, Helen J.
Kishikova, Lyudmila
Powell, Fiona L.
Wheatley, Sally P.
Chevassut, Timothy J.
EXPERIMENTAL HEMATOLOGY, 2011, 39 (03) : 330 - 338
[27] BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells
Lian, Guodong
Li, Leping
Shi, Yulong
Jing, Changqing
Liu, Jinglei
Guo, Xiaobo
Zhang, Qingqing
Dai, Tianyu
Ye, Fei
Wang, Yanyan
Chen, Man
INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 52 (03) : 804 - 814
[28] Preclinical studies investigating the efficacy of GSK461364A, an inhibitor of Polo-like kinase-1, for the prevention of breast cancer brain metastases
Palmieri, Diane
Hua, Emily
Qian, Yongzhen
Herring, Jeanne
Liewehr, David
Steinberg, Seth
Laquerre, Sylvie
Dar, Mohammed
Steeg, Patricia
CANCER RESEARCH, 2009, 69
[29] Biomarkers of response to abiraterone and the polo-like kinase 1 (PLK1) inhibitor onvansertib in metastatic castration resistant prostate cancer (mCRPC) patients
Ridinger, Maya
Samuelsz, Errin
Croucher, Peter J.
Erlander, Mark
Ruffner, Katherine
Einstein, David J.
CANCER RESEARCH, 2022, 82 (12)
[30] A RANDOMIZED PHASE II TRIAL OF THE NOVEL POLO-LIKE KINASE 1 INHIBITOR BI 2536 IN CHEMONAIVE PATIENTS WITH UNRESECTABLE ADVANCED PANCREATIC CANCER: A STUDY IN COOPERATION WITH THE CESAR NETWORK OF INVESTIGATORS
Mross, K.
Dittrich, C.
Aulitzky, W.
Strumberg, D.
Schuette, J.
Schmid, R. M.
Hollerbach, S.
Merger, M.
Munzert, G.
Scheulen, M. E.
ANNALS OF ONCOLOGY, 2008, 19 : 163 - 163

← 1 2 3 4 5 →